Recombinant Human IA2 Protein (365AA,N-6His)

Name: Recombinant Human IA2 Protein (365AA,N-6His)
Brand: Beta LifeScience
SKU: BL-1572NP
Availability: InStock

BL-1572NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Islet Cell Antigen 2/Protein Tyrosine Phosphatase Receptor-type N is produced by our E.coli expression system and the target gene encoding Arg576-Gln950 is expressed with a 6His tag at the N-terminus.
Accession	Q16849
Synonym	Receptor-type tyrosine-protein phosphatase-like N; R-PTP-N; Islet cell antigen 512; ICA 512; Islet cell autoantigen 3; PTP IA-2; PTPRN; ICA3; ICA512
Gene Background	Receptor-type tyrosine-protein phosphatase-like N (PTPRN) belongs to the protein-tyrosine phosphatase family and receptor class 8 subfamily. PTPRN contains 1 tyrosine-protein phosphatase domain, is expressed in neuroendocrine cells only. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. It implicated in neuroendocrine secretory processes. It may be involved in processes specific for neurosecretory granules, such as their biogenesis, trafficking or regulated exocytosis or may have a general role in neuroendocrine functions. It seems to lack intrinsic enzyme activity, may play a role in the regulation of secretory granules via its interaction with SNTB2. This PTP was found to be an autoantigen that is reactive with insulin-dependent diabetes mellitus (IDDM) patient sera, and thus may be a potential target of autoimmunity in diabetes mellitus.
Molecular Mass	44.6 KDa
Apmol Mass	50 KDa, reducing conditions
Formulation	Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Plays a role in vesicle-mediated secretory processes. Required for normal accumulation of secretory vesicles in hippocampus, pituitary and pancreatic islets. Required for the accumulation of normal levels of insulin-containing vesicles and preventing their degradation. Plays a role in insulin secretion in response to glucose stimuli. Required for normal accumulation of the neurotransmitters norepinephrine, dopamine and serotonin in the brain. In females, but not in males, required for normal accumulation and secretion of pituitary hormones, such as luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Required to maintain normal levels of renin expression and renin release. Seems to lack intrinsic enzyme activity. May regulate catalytic active protein-tyrosine phosphatases such as PTPRA through dimerization.; ICA512-TMF regulates dynamics and exocytosis of insulin secretory granules (SGs); binding of ICA512-TMF to SNTB2/beta-2-syntrophin is proposed to restrain SGs mobility and exocytosis by tethering them to the actin cytoskeleton depending on UTRN; the function is inhibited by cytoplasmic ICA512-CFF dimerizing with ICA512-TMF and displacing SNTB2.; ICA512-CCF translocated to the nucleus promotes expression of insulin and other granule-related genes; the function implicates binding to and regulating activity of STAT5B probably by preventing its dephosphorylation and potentially by inducing its sumoylation by recruiting PIAS4. Enhances pancreatic beta-cell proliferation by converging with signaling by STAT5B and STAT3. ICA512-CCF located in the cytoplasm regulates dynamics and exocytosis of insulin secretory granules (SGs) by dimerizing with ICA512-TMF and displacing SNTB2 thus enhancing SGs mobility and exocytosis.
Subcellular Location	Membrane; Single-pass type I membrane protein. Cytoplasmic vesicle, secretory vesicle membrane; Single-pass type I membrane protein. Perikaryon. Cell projection, axon. Cell junction, synapse. Cell membrane; Single-pass type I membrane protein. Endosome.; [ICA512-transmembrane fragment]: Cytoplasmic vesicle, secretory vesicle membrane.; [ICA512-cleaved cytosolic fragment]: Nucleus.
Protein Families	Protein-tyrosine phosphatase family, Receptor class 8 subfamily
Database References	HGNC: 9676 OMIM: 601773 KEGG: hsa:5798 STRING: 9606.ENSP00000295718 UniGene: PMID: 27881117 Identification of amino acids contributing to distinct epitopes on IA-2, with both HLA-DR and HLA-DQ alleles influencing epitope specificity. PMID: 26564179 RESP18HD is required for efficient sorting of ICA512 to secretory granules: RESP18HD is a key determinant for ICA512 granule targeting. PMID: 26836020 The binding of CREB to the promoter region, -216 to +115, enhanced IA-2 transcription by more than fivefold. PMID: 25528004 Kaplan-Meier survival curves estimated a worst pancreas graft survival for patients with positive IA-2 antibodies versus those patients with negative auto-antibodies and GAD65+ auto-antibodies after simultaneous pancreas kidney transplantation. PMID: 25645784 Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. PMID: 23396399 identification of cysteines that are critical for IA-2A binding of autoantibodies in patients with newly diagnosed type 1 diabetes PMID: 22966073 the IA-2A autoantibody response in children is intense with rapid maturation against immunogenic epitopes and a strong association with diabetes development PMID: 23110943 Letter: report lack of anti-IA2 autoantibodies in primary antiphospholipid syndrome. PMID: 21442164 analysis of protein-protein interactions in crystals of the human receptor-type protein tyrosine phosphatase ICA512 ectodomain PMID: 21935384 ZnT8A, GADA and IA-2A are autoantibodies that may have a role in successful pancreas graft survival PMID: 21792090 In families with type 1 diabetes, there was a female predominance and more family history of associated autoimmune diseases (AAIDs) in the group with AAIDs, and less frequent anti-IA-2 antibodies PMID: 21744463 Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). PMID: 21577013 Studies indicate that T1DM can be detected by determining four autoantibodies, namely those antibodies against insulin, glutamic acid decarboxylase 65, insulinoma antigen (IA)-2 (ICA512) and the zinc transporter ZnT8. PMID: 21073664 Risk of autoantibody seroconversion among children followed in DPT-1 is age dependent PMID: 21270193 Data show that significantly increased expression of MCP-1, IL-2 and PTPR-N was observed in Tourette's syndrome cases. PMID: 20193755 T cells stimulated in vitro by the IA-2 epitope express IFN-gamma when restimulated by the similar rotavirus VP7 peptide. PMID: 20083660 Report a chimeric assay providing an efficient and economical technique to screen for islet autoantibodies reacting with IA-2 and ZnT8 in type 1 diabetes mellitus. PMID: 20035758 ICA512(IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. PMID: 11908951 Autoantibodies to IA-2 in type 1 diabetes: measurements with a new enzyme-linked immunosorbent assay. PMID: 12021115 BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India. PMID: 12021127 findings indicate that glutamine at position 862, and residues 876-880 of the WPD loop of IA-2 are important for several of the IA-2 specific PTP domain epitopes PMID: 14624760 The islet cell autoantigen 512 (ICA512)/IA-2 is a receptor tyrosine phosphatase-like protein associated with the insulin secretory granules (SGs) of pancreatic beta-cells. PMID: 15596545 Measuring IA-2A is useful for the diagnosis and prognosis of type 1 diabetes in Japanese. PMID: 15620435 IA-2 is an important regulator of dense core vesicle number and glucose-induced and basal insulin secretion in beta cells. PMID: 15939893 identification of proteins that interact with IA-2, the IA-2 interactome; the IA-2 interactome based on pull-down experiments, currently consists of 12 proteins; identification of these interacting proteins provides clues as to how IA-2 functions PMID: 16273344 Autoantibodies in type 1 diabetes for this protein provide a model for other autoimmune diseases. PMID: 18373080 HLA class II alleles strongly influence the prevalence of IA-2A in type 1 diabetes. PMID: 18504544 Inexpensive, nonradioactive method for the detection of autoantibodies cell-prepared PTPRN (also known as IA-2) in diabetics. PMID: 18535195 The study identifies a region of IA-2 frequently recognised by antibodies in Type 1 diabetes and demonstrates that these responses are associated with T-cells secreting IL-10 in response to a neighbouring determinant. PMID: 19447008

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.